Clinical Trial Update: Fenofibrate Role in the Prophylaxis From Peripheral Neuropathy Induced by Bortezomib, Lenalidomide and Dexamethasone (VRd) Protocol in the Treatment of Patients With Multiple Myeloma (MM) [Phase 4]

View source ↗

Summary

This Phase 4 clinical trial investigates whether Fenofibrate can prevent peripheral neuropathy induced by VRd (bortezomib, lenalidomide, dexamethasone) therapy …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Peripheral Neuropathy

Drugs mentioned

• FENOFIBRATE (Fenofibrate)

Snippet

Sponsor: Tanta University | Conditions: Peripheral Neuropathy, Multiple Myeloma, Neoplasms | Phase 4 | Status: RECRUITING